13.59
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Urogen Pharma (NASDAQ:URGN) Short Interest Down 29.9% in May - Defense World
HC Wainwright Decreases Earnings Estimates for Urogen Pharma - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - FinancialContent
UroGen Pharma Ltd (NASDAQ: URGN) Stock: A Value Hunter’s Investment? - Stocksregister
H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - MSN
UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade - Defense World
UroGen Pharma (NASDAQ:URGN) Upgraded to “Buy” at HC Wainwright - Defense World
UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
UroGen Investor Drops Cancer Drug Suit Following FDA Approval - Bloomberg Law News
Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about ... - Eagle-Tribune
Investors who lost money on UroGen Pharma Ltd.(URGN) should - GlobeNewswire
URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for - GlobeNewswire
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action - ACCESS Newswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target - MarketScreener
UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025URGN - PR Newswire
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Scotiabank Raises UroGen Pharma (NASDAQ:URGN) Price Target to $47.00 - Defense World
UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
UroGen Pharma (NASDAQ:URGN) Shares Gap Up After Analyst Upgrade - Defense World
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Kilgore News Herald
UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Victoria Advocate
Goldman Sachs Increases Price Target for UroGen Pharma (URGN) Af - GuruFocus
UroGen Pharma Gains Amid Analyst Ratings in Biopharma Sector Russell 1000 - Kalkine Media
UroGen Pharma price target raised to $31 from $10 at Oppenheimer - Investing.com India
UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote - insights.citeline.com
UroGen Pharma (URGN) Receives Price Target Boost to $31 After Zusduri Approval | URGN Stock News - GuruFocus
Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week - Benzinga
UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | URGN Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha
Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt - GuruFocus
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA - BioWorld MedTech
UroGen Pharma (URGN) Soars After FDA Approval and Price Target B - GuruFocus
Why Is UroGen Pharma Stock Trading Higher On Friday?UroGen Pharma (NASDAQ:URGN) - Benzinga
Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Optimism | URGN Stock News - GuruFocus
UroGen Pharma (URGN) Stock Outlook: Guggenheim Raises Price Target | URGN Stock News - GuruFocus
URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider
UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20 - Asianet Newsable
UroGen continues to climb after bladder cancer drug approval - Seeking Alpha
Transcript : UroGen Pharma Ltd.Special Call - marketscreener.com
UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote - Fierce Pharma
UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital - Defense World
UroGen Pharma stock soars as FDA approves Zusduri despite negative panel vote - Investing.com India
FDA approves UroGen Pharma’s bladder cancer treatment - Investing.com
UroGen Pharma stock price target raised to $47 from $23 at Scotiabank - Investing.com
Guggenheim Boosts UroGen Pharma (URGN) Price Target Following FDA Approval | URGN Stock News - GuruFocus
FDA greenlights UroGen’s Zusduri for recurrent bladder cancer patients - The Pharma Letter
UroGen Pharma Ltd. Sued for Securities Law ViolationsContact Levi & Korsinsky Before July 28, 2025 to Discuss Your RightsURGN - Morningstar
The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline – URGN - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - GlobeNewswire
Health Care Climbs Amid Deal ActivityHealth Care Roundup - marketscreener.com
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
UroGen soars 50% on FDA approval of historic bladder cancer treatment - Investing.com Australia
UroGen Pharma (URGN) Gains After FDA Greenlights Zusduri | URGN Stock News - GuruFocus
US FDA approves UroGen's bladder cancer drug - marketscreener.com
Scotiabank Raises UroGen Pharma Price Target to $47 From $23, Maintains Sector Outperform Rating - marketscreener.com
FDA okays UroGen's bladder cancer treatment after narrow ODAC rebuff - FirstWord Pharma
FDA approves UroGen’s ZUSDURI for bladder cancer treatment - Investing.com Australia
U.S. FDA Approves UroGen Pharma Ltd.'s ZUSDuri?? for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-NMIBC) - marketscreener.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):